Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus [Yahoo! Finance]
Sunshine Biopharma Inc. (SBFM)
NASDAQ:AMEX Investor Relations:
sunshinebiopharma.com/press-releases.html
Company Research
Source: Yahoo! Finance
researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has developed an orally active protease inhibitor with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2). There are still unmet medical needs for agents to combat SARS-CoV-2 infections. SARS-CoV-2 is the etiologic agent of COVID-19 and one of three types of Coronavirus that cause Severe Acute Respiratory Syndrome (SARS). SARS-CoV-2 undergoes mutation at a rapid rate, which leads to the continuous emergence of variants of concern (VOC) posing a significant threat to public health. In addition, certain populations, such as immunocompromised patients who are susceptible to severe and prolonged infections, may not respond well to current therapies or vaccines. For high-risk patients, blocking early infection at home may prevent rapid disease progression and reduce hospitalization. PLpro is an alternative therapeutic target fo
Show less
Read more
Impact Snapshot
Event Time:
SBFM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SBFM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SBFM alerts
High impacting Sunshine Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
SBFM
News
- Sunshine Biopharma Announces Novel Inhibitor for Sars CoronavirusAccesswire
- Sunshine Biopharma, Inc. (NASDAQ: SBFM) had its "buy" rating re-affirmed by analysts at Aegis. They now have a $15.00 price target on the stock.MarketBeat
- Sunshine Biopharma Launches a New Generic Prescription Drug Accesswire
- Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma [Yahoo! Finance]Yahoo! Finance
- Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular CarcinomaAccesswire
SBFM
Sec Filings
- 12/10/24 - Form 8-K
- 11/14/24 - Form SC
- 11/12/24 - Form 424B4
- SBFM's page on the SEC website